Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis

Objective To investigate if the addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) could improve patient outcomes. Methods A prospective, randomized, controlled study was conducted in patients with MDR-TB. Treatment was for 18 months. Patient...

Full description

Bibliographic Details
Main Authors:	Ge Yao, Muxin Zhu, Qi Nie, Nanshan Chen, Shengjin Tu, Yong Zhou, Fan Xiao, Yuan Liu, Xi Li, Hua Chen
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-01-01
Series:	Journal of International Medical Research
Online Access:	https://doi.org/10.1177/03000605221148416

Similar Items

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Bedaquiline and clofazimine: successes and challenges
by: Norbert Ndjeka, et al.
Published: (2020-08-01)

Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients
by: Yuanyuan Shang, et al.
Published: (2023-06-01)

Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis
by: Md Mahmudul Islam, et al.
Published: (2024-01-01)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
by: Rong Li, et al.
Published: (2023-08-01)

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
by: Sonnenkalb, L, et al.
Published: (2023)

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01)

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
by: Camus Nimmo, et al.
Published: (2024-02-01)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
by: Jing-Tao Gao, et al.
Published: (2021-03-01)

Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis
by: Liang Fu, et al.
Published: (2021-10-01)

Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
by: Lara J Wolfson, et al.
Published: (2015-01-01)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
by: Hossein Hatami, et al.
Published: (2022-05-01)

Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China
by: Guo Y, et al.
Published: (2023-12-01)

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
by: J. Snobre, et al.
Published: (2023-06-01)

Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis
by: N. Ismail, et al.
Published: (2018-10-01)

Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review
by: Rhea Veda Nugraha, et al.
Published: (2021-05-01)

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis
by: Punam Jakhar , Rajesh Chaudhary , Kalpana Baijal , Rajveer S Rathore , Susheel Kumar
Published: (2023-09-01)

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience
by: Alena Skrahina, et al.
Published: (2016-01-01)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
by: Shereen Katrak, et al.
Published: (2021-05-01)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
by: Lawrence Mbuagbaw, et al.
Published: (2019-05-01)

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

Clofazimine for the treatment of tuberculosis
by: Jacob A. M. Stadler, et al.
Published: (2023-02-01)

Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
by: Shynar M. Maretbayeva, et al.
Published: (2021-12-01)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
by: Oki Nugraha Putra, et al.
Published: (2021-10-01)

First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda
by: Jupiter Marina Kabahita, et al.
Published: (2022-05-01)

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia
by: Gunar Günther, et al.
Published: (2024-03-01)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
by: Jay Achar, et al.
Published: (2017-10-01)

Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis
by: V. A. Aksenova, et al.
Published: (2021-10-01)

Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis
by: Lei Zhang, et al.
Published: (2023-10-01)

Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis
by: Camus Nimmo, PhD, et al.
Published: (2020-08-01)

Phenotypic drug susceptibility characterization and clinical outcomes of tuberculosis strains with A-probe mutation by GeneXpert MTB/RIF
by: Qi Nie, et al.
Published: (2023-11-01)

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China
by: Qianqian Fan, et al.
Published: (2019-01-01)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
by: Ge Shao, et al.
Published: (2023-03-01)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
by: Yewon Kang, et al.
Published: (2022-01-01)

Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial
by: Xubin Zheng, et al.
Published: (2023-12-01)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
by: Citra Cesilia, et al.
Published: (2023-01-01)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
by: Jinmeng Li, et al.
Published: (2021-09-01)

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01)